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ABSTRACT
Bisphosphonates, potent antiresorptive agents, have been found to be associated with mortality reduction. Accelerated bone loss is, in
itself, an independent predictor of mortality risk, but the relationship between bisphosphonates, bone loss, and mortality is unknown. This
study aimed to determine whether the association between bisphosphonates and mortality is mediated by a reduction in the rate of bone
loss. Participants from the population‐based Canadian Multicentre Osteoporosis Study were followed prospectively between1996 and
2011. Comorbidities and lifestyle factors were collected at baseline and bone mineral density (BMD) at baseline and at years 3 (for those
aged 40 to 60 years), 5, and 10. Rate of bone loss was calculated using linear regression. Information on medication use was obtained
yearly. Bisphosphonate users grouped into nitrogen bisphosphonates (nBP; alendronate or risedronate) and etidronate and non‐users
(NoRx) were matched by propensity score, including all baseline factors as well as time of treatment. Cox’s proportional hazards models,
unadjusted and adjusted for annual rate of bone loss, were used to determine the association between nBP and etidronate versus NoRx.
For the treatment groups with significant mortality risk reduction, the percent of mortality reduction mediated by a reduction in the rate of
bone loss was estimated using a causal mediation analysis. There were 271 pairs of nBP and matched NoRx and 327 pairs of etidronate
and matched NoRx. nBP but not etidronate use was associated with significant mortality risk reduction (hazard ratios [HR]= 0.61 [95%
confidence interval 0.39–0.96] and 1.35 [95% CI 0.86–2.11] for nBP and etidronate, respectively). Rapid bone loss was associated with more
than 2‐fold increased mortality risk compared with no loss. Mediation analysis indicated that 39% (95% CI 7%–84%) of the nBP association
with mortality was related to a reduction in the rate of bone loss. This finding provides an insight into the mechanism of the relationship
between nBP and survival benefit in osteoporotic patients. © 2019 American Society for Bone and Mineral Research.
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Introduction
Osteoporotic (fragility) fractures are very common, affecting3 in 5 women and 1 in 3 men over the age of 50 years.(1)
Furthermore, their prevalence is expected to rise as a
consequence of increasing life expectancy and thus the
number of individuals at risk.(2) The burden of osteoporotic
fracture resides not only in their increased risk of subsequent
fracture(3–5) but also in increased mortality risk.(6–9)
Bisphosphonates are currently considered first‐line treatment
for osteoporosis worldwide(10,11) with abundant evidence of their
ability to reduce both vertebral and nonvertebral fracture
risk.(12–14) More recently, bisphosphonates have been also linked
to improved survival.(15,16) The first evidence of a positive
association between bisphosphonate use and survival came
from a randomized control trial (RCT) of zoledronic acid post‐hip
fracture.(15) In this trial, zoledronic acid was associated with a 28%
mortality risk reduction compared with placebo.(15) Subsequently,
a meta‐analysis of anti‐osteoporosis medication from eight RCTs
(including risedronate, zoledronic acid, denosumab, and strontium
ranelate)(16) found a pooled benefit (~11%) of these agents on
mortality risk.(16) Interestingly, in this meta‐analysis, the mortality
risk reduction was predominantly observed in the trials with the
highest background mortality risk. However, a more recent RCT of
zoledronic acid in women with osteopenia has also shown a
mortality risk reduction of ~35% over a longer follow‐up time of 6
years, although it did not quite reach statistical significance.(17) A
positive association between bisphosphonates and mortality risk
has also been reported in several observational osteoporosis
cohorts,(18–20) a fracture liaison service setting,(21) and registry‐
based studies.(22,23)
The mechanism by which bisphosphonates impact survival is not
fully understood. Several hypotheses have been proposed to
explain this effect. The most obvious explanation would be through
a reduction in the rate of subsequent fractures. However, in the
zoledronic acid RCT, only 8% of total deaths prevented were
estimated to be mediated through this mechanism.(24) It is also
possible that a reduction in the rate of bone loss may explain the
mortality risk reduction observed in bisphosphonate‐treated
groups. Excessive bone loss is associated with increased mortality
risk in both the general population as well as post‐fracture.(25,26)
However, there is no information as to whether bone loss may play
a role in mortality risk reduction associated with bisphosphonate
use. Thus, this study aimed to determine whether the association
between bisphosphonates and survival is mediated by a reduction
in the rate of bone loss.
Materials and Methods
Subjects and setting
The study population consisted of women and men aged
50 years and older participating in the Canadian Multicentre
Osteoporosis Study (CaMos), an ongoing prospective popula-
tion‐based study that was started in 1995. Participants were
recruited randomly using residential telephone lists from the
region surrounding nine urban centers in Canada. A detailed
description of the study design and population sampling has
been published previously.(27)
The present study included participants who had at least two
bone mineral density measurements and who either used one of
bisphosphonates available (alendronate, risedronate, or etidronate)
or did not use any bone‐related medication. Alendronate and
etidronate were available at baseline, whereas risedronate became
available later and participants started using it on average 9 years
(±3 years) later, resulting in a smaller number of risedronate users.
Medication was classified, based on mechanism of action, as
nitrogen bisphosphonates (alendronate or risedronate) and non‐
nitrogen (etidronate) bisphosphonate. To avoid misclassification,
all the participants who switched between bisphosphonate types
were excluded. Furthermore, this study used an intention‐to‐treat
approach. Thus, participants were analyzed in the treatment group
they were initially assigned regardless of whether they adhere or
not to treatment.
A number of bisphosphonates and other treatments were
excluded because of small numbers of users, namely clodronate,
pamidronate, zoledronic acid, calcitonin, denosumab, raloxifene,
tamoxifen, testosterone, or other sex hormone therapy.
Of the 9423 participants recruited, 7689 aged 50 years or
older were screened for medication uptake and had had at
least two bone mineral density measurements. After the first
screening, it was found that very few men met the study
criteria (68 on nitrogen bisphosphonate and 87 on etidronate),
and therefore analysis was restricted to women only (Fig. 1).
CaMos was approved by the Ethics Committee of McGill
University and at each participating center.
Outcomes and risk factors
A standardized interviewer‐administered questionnaire was
obtained at baseline (1995–97). Information was obtained on
lifestyle factors (ie, smoking, physical activity), demographics,
education, comorbidities, and medication use. In addition to this
structured questionnaire, each participant had a clinical visit that
included anthropometric (ie, height, weight) and bone mineral
density (femoral neck and lumbar spine) measurements.
This information was subsequently obtained in years 5 and
10. In those aged 40 to 60 years at entry, another clinical visit
was conducted at year 3. Yearly postal self‐administered
questionnaires for incident fractures and medications were
obtained between clinical visits.
Bone mineral density assessment
Bone mineral density was measured as femoral neck and lumbar
spine areal bone mineral density (BMD) at baseline and then
subsequently in years 3 (40 to 60 years of age), 5, and 10. BMD
assessment was performed by dual‐energy X‐ray absorptiometry
(DXA; Discovery W, Hologic, Bedford, MA, USA). Standardization
between DXA scanners was assessed by scanning a single
phantom, which was circulated among centers.(28)
Participants and/or their primary care physician received a
copy of the BMD report performed at baseline and all
subsequent visits. They did not receive any formal fracture
risk assessment or management suggestions from the CaMOS
investigators.
The annual percent change in bone mineral density was
calculated for each individual participant using a linear
regression model to determine the intercept (at baseline) and
the slope of BMD over time for both femoral neck and lumbar
spine sites. The annual rate of bone loss was calculated as the
ratio between the slope and the intercept. The annual percent
bone loss was compared according to medication use. For the
nonmedication users, all BMD measurements were used in
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calculation, whereas for the medication users, the rate of bone
loss was calculated based on 1 measurement before first visit
with medication and all the subsequent BMD measurements
following that visit. For participants who started medication
after the year 10 visit (n= 294), this could not be calculated.
Participants with at least one BMD measurement were
included in a sensitivity analysis. Their individual rate of bone
loss at the site of femoral neck was estimated using mixed‐
effects models. These models estimate a rate of bone loss in
individuals with one measurement based on the general trend
of the participants who have all or almost all measurements.
Fracture ascertainment
Self‐reported incident clinical fractures were obtained yearly
and at clinical visits. Information on the date, site, and
circumstance of the fracture was obtained by interview and
an X‐ray report sought. The majority of fractures (78%) were
confirmed by medical report.(29) This study included only
incident fragility fractures. Skull, sternum, finger, and toe
fractures were excluded.
Mortality ascertainment
Deaths occurring during the study follow‐up were ascertained
by contact with the next of kin or proxy if the yearly
questionnaire was not returned. In some centers, deaths were
verified by obituaries.
Statistical analysis
Nitrogen bisphosphonates (nBP; alendronate and risedronate)
and non‐nBP (etidronate), because of the higher potency of the
former and different mechanism of action, were analyzed
separately.
Baseline characteristics were examined for the two classes of
bisphosphonates (nBP and non‐nBP) in comparison to non-
treated participants (NoRx) (t tests for continuous and chi‐
square tests for categorical variables). Because of significant
differences in baseline characteristics between treatment
groups, participants who received medication during the
follow‐up were matched 1:1 to NoRx based on propensity
score. Propensity score was calculated using a multivariate
logistic regression model with treatment as outcome and
adjustment for all baseline characteristics. The treated and not‐
treated participants were then matched using the SAS macro
“gmatch” based on a propensity score difference of less than
half SD and the condition that not‐treated participants should
be alive when the treated participants started treatment.
The relationship between medication use, annual rate of
bone loss, and mortality risk was assessed in two nested sets of
nBP and non‐nBP users (etidronate) matched 1:1 to NoRx
participants using a single causal mediation analysis.(30) Briefly,
mediation analysis seeks to explain the underlying mechanism
between an independent and dependent variable by inclusion
of a third variable, which represents the hypothesized
mediator. The mediation model thus tests the hypothesis that
the independent variable influences the mediator variable,
which in turn influences the dependent variable. According to
this model, a variable is likely to be a mediator upon meeting
three conditions: the independent variable is significantly
associated with the mediator; the mediator is significantly
associated with the dependent variable; and the association
between independent and dependent variable decreases and
become not significant in the presence of mediator. This study
utilizes this methodology to test whether the relationship
between bisphosphonates (independent variable) and survival
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3196
1268   Hormone Therapy
Excluded
5526   Women enrolled in CaMOS 1995-2013
1311 Bisphosphonates 1019 No Treatment  
1196 Included in the analysis after 1:1 matching
Potential controls for bisphosphonate387 Nitrogen Bisphosphonate (alendronate/risedronate)
337 Etidronate
587 Switchers (etidronate/nitrogen bisphosphonates) 
587 Switchers excluded
542 Alendronate or Risedronate and not treated pairs
654 Etidronate and not treated pairs
1720   Do not have ≥ 2 BMD 
208   Bone related medication ^
^ The list of bone related medication not eligible includes: pamidronate, clodronate, calcitonin, SERMS, Hormone therapy and Tamoxifen
Fig. 1. Flow chart of study participants.
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(dependent variable) is mediated by a reduction in the annual
rate of bone loss (mediator variable).(31) Four models were thus
constructed: 1) a linear regression model of treatment with
annual percent change of bone loss as the outcome (path a); 2)
a Cox’s proportional hazards model of annual percent bone loss
with survival as the outcome (path b); 3) a Cox’s proportional
hazards model of treatment and survival without adjustment
for annual percent bone loss (path c); 4) a multivariate Cox’s
proportional hazards model of treatment with adjustment for
annual percent bone loss with survival as outcome (path c’)
(Fig. 2). Given that the treated participants were matched by
propensity score with nontreated participants, there were few
unbalanced variables. Double adjustment has been recom-
mended for all variables with standardized mean difference
(SMD)≥ 0.10 after matching.(32) To be more conservative, we
have adjusted for all variables with a SMD≥ 0.03 after
matching. All four mediation models described above were
adjusted for the variables with SMD≥ 0.03 (paths a, b, c, c’).(33)
Follow‐up was calculated from the time of medication start for
both treated and nontreated. For nontreated, this starting point
was obtained by the addition to baseline date his/her “pair’s”
time of medication commencement. In each survival model,
the strength of the association between treatment, annual
percent bone change, and survival was assessed by the hazard
ratio and the 95% confidence interval (CI).
If the associations between treatment and both survival and
bone loss reduction were significant, a causal mediation analysis
was performed using the % mediate Macro publicly available
(https://www.hsph.harvard.edu/donna-spiegelman/software/
mediate). This analysis estimates the point and interval estimates
of the percent of the treatment effect mediated by the mediator
(ie, annual percent change in bone mineral density) using Cox
regression survival analysis.
All statistical analyses were performed using SAS version 9.4
for Windows (SAS Institute, Cary, NC, USA).
Results
This study included 1743 women aged 50 years or older who
had at least two BMD measurements, followed for a median
of 15.0 years (interquartile range [IQR] 10.5 to 15.0). During this
follow‐up, 454 (26%) women experienced an incident fracture, and
241 (14%) died. BMD declined at the site of femoral neck with a
median of –0.38%/year (IQR –1.00 to 0.22) and increased slightly at
the lumbar spine with a median of+0.22%/year (IQR –0.39 to 0.92).
Women were classified according to treatment as nBP
(n= 387), etidronate users (n= 337), and NoRx (n= 1019). All
bisphosphonate users had several factors associated with
poorer survival: significantly lower femoral neck BMD, weight,
and more prior fractures than NoRx individuals. They also had
several factors associated with “healthy users,” such as better
education, lifestyle habits (less smoking, more exercise, and
more vitamin D use), and less cardiovascular disease and
diabetes (Table 1). To overcome this imbalance in character-
istics, treated participants were matched 1:1 to nontreated
participants based on a propensity score, which included age,
weight, femoral neck BMD, prior fractures, education, lifestyle
habits (smoking and exercise), and comorbidities.
There was no difference in the prevalence of treatment
across the nine study centers.
Etidronate versus matched nontreatment
Almost all etidronate users (327 of 337) were matched 1:1 by
propensity score to nontreated participants. After matching, all
baseline variables had a standardized mean difference less than
0.10, except age (nontreated were older) and smoking (more in
nontreated) (Table 1). Follow‐up time was comparable between
etidronate and nontreatment groups (9.0 years [IQR 6 to 13] for
etidronate and 9 years [IQR 6 to 12] for nontreatment, p= 0.7]).
The number of incident fractures were similar between
etidronate users and matched nonusers (53 [16%] for
etidronate users versus 43 [13%] for nonusers; adjusted hazard
ratio [HR]= 1.27 [95% CI 0.71–2.25]; p= 0.42).
Mortality rates were similar for etidronate and NoRx groups
(27 deaths/1000 person‐years follow‐up [95% CI 16–26] and 23
deaths/1000 person‐years follow‐up [95% CI 18–28] for
etidronate and NoRx, respectively]) (Fig. 3, Table 2).
Etidronate users had a significantly lower rate of bone loss
than NoRx for femoral neck (difference 0.29%/year [95% CI
0.06–0.52]) and lumbar spine (difference 0.56%/year [0.38‐0.75]).
Individuals with the highest rate of femoral neck bone loss had
increased risk of mortality compared with those with lower rate
◼ 4 BLIUC ET AL. Journal of Bone and Mineral Research
Rate of Bone Change
n-Bisphosphonate Survival




Proportion mortality mediated by bone loss reduction=39.1 (95%CI, 7.1-84.4) %
Survival
* all models were adjusted for all variables with SMD ≥ 0.03 
Fig. 2. Mediation models with path coefficients: a= regression model for treatment and rate of femoral neck bone loss; b= Cox’s model for rate of
bone loss and survival; c’= Cox’s model for treatment and survival adjusted for rate of femoral neck bone loss; c= Cox’s model for treatment and
survival not adjusted for rate of femoral neck bone loss. All models were adjusted for baseline characteristics with standardized mean difference
(SMD)≥ 0.3 (Table 1).
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of bone loss (Fig. 4B). By contrast, a higher rate of bone loss at
the site of lumbar spine was not associated with increased
mortality risk. However, because of the nonsignificant effect of
etidronate on survival, mediation analysis was not performed.
Nitrogen bisphosphonates versus matched
nontreatment
Of the 387 nitrogen bisphosphonate users, 271 could be
matched 1:1 to nontreated participants, all with two or more
BMD measurements. After matching, the standardized mean
differences between variables were less than 0.10 except for
neurological conditions (more prevalent in treated), cancer
(more prevalent in nontreated), and smoking (more prevalent
in nontreated) (Table 1). Follow‐up time after medication start
was on average ~9 (IQR 7 to 12) years for nBP users and ~7 (IQR
5 to 10) years for nontreated.
The number of incident fractures was similar between
treated and nontreated (n= 50 [18%] for nBP users and
n= 53 [20%] for nonusers; p= 0.74). Fracture risk was similar
between treatment group (adjusted HR= 1.0 [95% CI
0.53–1.90]). However, there was an interaction between
treatment and baseline femoral neck BMD, and a subgroup
analysis of individuals with a T‐score ≤ –2.5 SD revealed a
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Table 1. Baseline Characteristics of Female Participants According to Medication Use




bisphosphonate No treatment SMD
Nitrogen
bisphosphonate No treatment SMD
No. of participants 387 1019 271 271
Agea (years) 64.8 (8.2) 65.6 (8.2) –0.09 65.2 (8.1) 65.1 (8.1) 0.01
Weighta (kg) 64.7 (11.2) 73.6 (14.1) –0.720 66.4 (11.4) 67.0 (11.8) –0.02
Higher educationb 114 (29.5) 214 (21) 0.178 75 (27.6) 70 (25.8) –0.06
Prior fractureb 115 (29.7) 261 (25.6) 0.090 83 (30.6) 80 (29.5) 0.010
FN BMDa (g/cm2) 0.64 (0.09) 0.73 (0.11) –0.850 0.66 (0.09) 0.66 (0.11) –0.06
LS BMDa (g/cm2) 0.82 (0.13) 0.97 (0.15) –0.972 0.85 (0.13) 0.85 (0.13) –0.02
Comorbiditiesb
Heart disease 18 (4.7) 71 (7.0) –0.169 11 (4.1) 13 (4.8) 0.02
Diabetes 11 (2.8) 83 (8.1) –0.212 9 (3.3) 14 (5.2) –0.09
Neurological 10 (2.6) 27 (2.6) –0.023 8 (2.9) 3 (1.1) 0.15
Respiratory 28 (7.2) 79 (7.8) 0.058 22 (8.1) 21 (7.7) 0.009
Cancer 19 (4.9) 67 (6.6) 0.034 10 (3.7) 17 (6.3) –0.10
Lifestyle factorsb
Exercise 253 (65.4) 585 (57.4) 0.166 171 (63.1) 169 (62.4) 0.03
Smoking 41 (10.6) 142 (13.9) –0.121 27 (10.1) 41 (15.1) –0.14
Etidronate and no treatment
Unmatched Matched
Etidronate No treatment SMD Etidronate No treatment SMD
No. of participants 337 1019 327 327
Agea (years) 67.7 (8.0) 65.6 (8.2) 0.276 67.7 (8.1) 68.6 (8.6) –0.10
Weighta (kg) 66.5 (12.2) 73.6 (14.1) –0.484 66.5 (12.1) 66.4 (10.9) 0.006
Higher educationb 67 (19.9) 214 (21.0) –0.03 67 (20.5) 57 (17.4) 0.08
Prior fractureb 98 (29.1) 261 (25.6) 0.093 98 (30.0) 102 (31.2) –0.03
FN BMDa (g/cm2) 0.64 (0.09) 0.73 (0.11) –0.879 0.64 (0.09) 0.64 (0.09) –0.02
LS BMDa (g/cm2) 0.86 (0.13) 0.97 (0.15) –0.760 0.86 (0.13) 0.87 (0.12) –0.05
Comorbiditiesb
Heart disease 31 (9.2) 71 (6.9) 0.0236 30 (9.2) 23 (7.0) 0.08
Diabetes 17 (5.0) 83 (8.1) –0.256 17 (5.2) 24 (7.3) –0.09
Neurological 14 (4.1) 27 (2.7) 0.057 14 (4.3) 11 (3.4) 0.05
Respiratory 32 (9.5) 79 (7.7) 0.097 32 (9.8) 32 (9.8) 0.00
Cancer 24 (7.1) 67 (6.5) 0.064 23 (7.0) 23 (7.0) 0.00
Lifestyle factorsb
Exercise 205 (60.8) 585 (57.4) 0.081 199 (60.9) 183 (56.0) 0.10
Smoking 38 (11.3) 142 (13.9) –0.074 36 (11.0) 50 (15.3) –0.130
SMD= standardized mean difference; FN= femoral neck; BMD= bone mineral density; LS= lumbar spine (L1 to L4).
aMean (SD).
bNo. (%); boldface represents variable unbalanced after matching (SMD >0.10).
l of Bone and Mineral Research BONE LOSS REDUCTION ASSOCIATED WITH REDUCED MORTALITY WITH NBP USE 200 n
nonsignificant but clinical relevant fracture risk reduction
associated with nBP use (adjusted HR= 0.40 [95%CI 0.12–1.32]).
Mortality rates were significantly lower for nBP users
(9 deaths/1000 person‐years [95% CI 5–13] compared with
NoRx (17 deaths/1000 person‐years [95% CI 11–22]; p= 0.03
(Table 2, Fig. 3). The rate of bone loss was significantly lower in
the nBP group compared with matched nontreated at both
femoral neck (difference 0.64%/year [95% CI 0.42–0.86];
p< 0.0001) and lumbar spine sites (difference 0.77%/year [95%
CI 0.56–0.98; p< 0.0001). Moreover, the highest quartile of bone
loss was associated with increased mortality risk (Fig. 4A). Cox
proportional hazard analysis determined that individuals with
accelerated rate of bone loss at the site of femoral neck (highest
quartile of bone loss) had a ~2‐fold higher mortality risk
compared with those who were in the lower bone loss quartiles
(HR= 2.0 [95% CI 1.1–3.6]) (Fig. 4A). Bone loss at the site of
lumbar spine was not associated with mortality risk.
Given the significant association between survival and both
nBP treatment and the annual rate of bone loss, a causal
mediation analysis was performed to determine the proportion
of mortality risk reduction mediated through a reduction in the
rate of bone loss. The relationship between treatment and
mortality not adjusted by hypothesized mediator (annual rate
of femoral neck BMD loss) was 0.61 (95% CI 0.39–0.96).
However, after adjusting for the mediator, the relationship
between treatment and mortality decreased and became
nonsignificant (HR= 0.74 [95% CI 0.46–1.19]). The proportion
of mortality risk reduction mediated by a reduction in the rate
of femoral neck bone loss was estimated at ~39% (95% CI
7%–84%) (Fig. 2). Adjustment for the unbalanced covariates
(SMD≥ 0.03) only marginally affected the causal relationship
between treatment, annual rate of bone loss, and survival
(Fig. 2). None of the baseline variables still unbalanced after
matching were significantly associated with mortality risk
(age‐adjusted HR: neurological conditions, 1.00 [95% CI
0.06–16.00]; p= 0.89; cancer, 1.52 [95% CI 0.62–3.77], and
smoking 0.91 [95% CI 0.31–2.64]) and thus could not mediate
the relationship between treatment and survival.
Sensitivity analysis
The participants who only had one BMD measurement (28% of
nontreated and 41% of those treated) were additionally
included in a sensitivity analysis. After matching, there were
487 nBP users matched 1:1 to nonusers and 466 etidronate
users matched 1:1 to nonusers (Supplemental Table S1). Similar
to the primary analysis, several baseline variables remained
unbalanced (SMD≥ 0.10) after matching (ie, age, weight,
diabetes). nBP treatment was associated with significant
reduction in mortality risk after adjustment for all baseline
variables excluding rate of BMD loss (Supplemental Table S2).
Similar to the primary analysis, after adjustment for the rate of
bone loss, the magnitude of the treatment effect on mortality
risk reduction decreased. The mediation model indicated that
the rate of bone loss mediated ~45% of the mortality rate
difference between treated and nontreated (percent mediated:
45.2% [95% CI 12.3%–83.0%]; p= 0.01). The findings of the
sensitivity analysis confirmed the robustness of the primary
analyses.
Etidronate use was not associated with lower mortality rates
than the matched nonusers (Supplemental Table S2).
Discussion
Recent evidence suggests that treatment with bisphospho-
nates is associated not only with fracture risk reduction but also
with a reduction in mortality risk. However, the mechanism
behind this association is not yet understood. In this observa-
tional study, nitrogen bisphosphonates were associated with
◼ 6 BLIUC ET AL. Journal of Bone and Mineral Research
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Fig. 3. Kaplan‐Meier survival curves for nitrogen bisphosphonates versus matched no treatment and etidronate versus no treatment.
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both a significantly lower mortality risk and a significantly lower
rate of bone loss compared with nontreated individuals with
similar baseline mortality risk. Individuals in the highest quartile
of bone loss were twice as likely to die compared with those
with lower rates of bone loss. Using mediation analysis to
combine these findings, approximately 39% of the mortality
risk reduction in the nitrogen bisphosphonate group was found
to be mediated through a reduction in the rate of bone loss.
Although causality cannot be confirmed in an observational
study, this statistical mediation analysis suggests that lower
rates of bone loss are associated with mortality reduction in
those on nitrogen bisphosphonates.
We have previously shown in the same cohort that nitrogen
bisphosphonates were associated with ~34% mortality risk
reduction, whereas etidronate, a non‐nitrogen bisphosphonate,
was not associated with any survival benefit.(34) Although this
finding suggested the existence of a possible “true” survival
benefit over the unavoidable “healthy bias” effect, it did not
provide any explanation for this effect. The risk of future fracture
investigated as potential mediator of mortality risk reduction
was not significantly reduced in treatment groups, perhaps
attributable to a higher baseline fracture risk in treated versus
nontreated individuals. However, the existence of a survival
benefit only in the group taking the most potent bispho-
sphonates, when analyzed in a direct head‐to‐head comparison
with non‐nitrogen bisphosphonate, together with the evidence
from previous studies that bone loss is associated with increased
mortality risk(25,26) led to the hypothesis that bone loss reduction
may contribute to the mortality risk reduction observed with
nitrogen bisphosphonates. The present study confirmed the
survival benefit of nitrogen bisphosphonates in a subset of
individuals, in whom rate of bone loss could be reliably assessed
through multiple bone mineral density tests. This study also
confirmed the associations between nitrogen bisphosphonates
and bone loss reduction, previously demonstrated in this
cohort.(35) An accelerated rate of bone loss was independently
associated with a ~2‐fold increased mortality risk. Importantly,
the addition of bone loss to the model of nitrogen bispho-
sphonates and survival lessened this association. According to
the statistical definition of mediation, a reduction in the rate of
bone loss is a partial mediator of the relationship between
nitrogen bisphosphonates and survival because: 1) nitrogen
bisphosphonates are associated with a reduction in the rate of
bone loss; 2) bone loss significantly predicts mortality risk; 3) the
relationship between nitrogen bisphosphonates and survival
was diminished and became not significant after adjusting for
bone loss; and 4) bone loss remained significantly associated
with survival in the final model.
Using a causal mediation analysis, it was estimated that
~39% of the mortality risk reduction associated with nitrogen
bisphosphonates was mediated by a reduction in the rate of
bone loss. In contrast with nitrogen bisphosphonate, etidronate
use was associated with a weaker effect on bone loss reduction
and was not associated with mortality risk reduction.
Notably, this mediation effect of bone loss was site specific.
This difference is probably driven by the spurious increase in
lumbar spine BMD due to degenerative disease that occurs in
the aging population. In the current study, the trajectories of
BMD change at the two bone sites were divergent, with loss
experienced only at the femoral neck site, but increase in
lumbar spine BMD, consistent with osteoarthritic lesions in the
lumbar spine that increase with age. Thus, lumbar spine BMD
change was not a predictor of mortality risk.
In the current study, the trajectories of BMD change at the
two bone sites were divergent, with loss experienced only at
the femoral neck site, consistent with osteoarthritic lesions,
which increase with age. Because of the same reasons, lumbar
spine BMD change was not a predictor of mortality risk.
The association between femoral neck bone loss and mortality
risk has been previously demonstrated in both individuals with
and without fracture.(25,26) The mechanism behind this association
is most likely multifactorial. The high bone turnover associated
with bone loss may lead to release of heavy metals from bone,(36)
which subsequently predisposes to cardiovascular risk.(37) Several
articles have reported bone loss as a component of the geriatric
frailty syndrome characterized by deterioration in physical
function and activity with an increased propensity for falling,
fracture, and mortality risk.(38–40) It has been proposed that the
mechanism behind the geriatric syndrome may be the presence
of a chronic low inflammatory state, which subsequently leads to
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Fig. 4. Hazard ratios of mortality for quartiles of femoral neck bone loss in nitrogen bisphosphonates and no treatment (A) and etidronate and no
treatment (B).
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bone loss, disability, and increased fracture risk and mortality.
Chronic inflammation is characterized by overproduction of
cytokines such as IL‐1, Il‐6, and TNF‐α, which not only perpetuate
the inflammatory state but also activate bone resorption and
inhibition of bone‐building mechanisms.(41) Bisphosphonates,
besides their antiresorptive effect on bone, also have anti‐
inflammatory properties.(42) In vitro studies indicated that these
agents impair macrophage differentiation and promote macro-
phage cytotoxicity and apoptosis. In vivo, nitrogen bispho-
sphonates induce a pro‐inflammatory effect in the short term,
but chronic administration may suppress pro‐inflammatory
cytokines. A recent study reported that treatment with bispho-
sphonates for 1 year was associated with a significant reduction in
plasma IL‐6, IL‐17, and IL‐23 compared with controls.(43)
Besides the anti‐inflammatory effect discussed above, some
evidence suggests that bisphosphonates may have an effect on
the immune system. In a recent study, treatment with zoledronic
acid was associated with activation of gamma delta T cells,
which are involved in the immune defense against infection.(44)
Furthermore, in a post hoc analysis of the potential mediators of
the mortality risk reduction observed in patients treated with
zoledronic acid after hip fracture, treatment was associated with
a significant reduction in deaths due to pneumonia, despite a
similar incidence of the condition.(24) Notably, in a recent RCT of
zoledronic acid in women with osteopenia, treatment was
associated with a significant reduction in the incidence of cancer
(HR= 0.67 [95% CI 0.50–0.89]).(17)
It is most likely that other mechanisms are involved in the
mortality risk reduction associated with nitrogen bisphospho-
nates. There is a clear epidemiological association between bone
loss and arterial calcification(45) that suggest common pathways,
although the mechanism is not fully understood. Data from
randomized controlled studies suggest a reduction of cardio-
vascular mortality risk in patients treated with risedronate and
zoledronate.(24,46) Bisphosphonates have also been associated
with a reduced risk of myocardial infarction in a case‐control
study of hip and vertebral fractures(47) and in patients with
rheumatoid arthritis.(48) In the RCT of zoledronic acid in women
with osteopenia, treatment was associated with a nonsignificant
reduction in the incidence of myocardial infarction and stroke.(17)
Furthermore, in a recent RCT comparing romososumab and
alendronate, the incidence of severe cardiovascular events was
higher in the romososumab than alendronate groups, despite a
similar cardiovascular risk at baseline.(49) As romososumab was
not associated with increased cardiovascular events in the
previous and larger FRAME trial (romososumab versus placebo),
it is possible that the increased cardiovascular events observed
in romososumab versus alendronate may be attributable to a
reduction in cardiovascular events for alendronate. However, in a
recent meta‐analysis of RCTs, bisphosphonates were not
associated with a reduction in major cardiovascular events,
although these events were not formally adjudicated.(50) Thus,
there is still uncertainty about any of these potential
mechanisms.
This study has several strengths. CaMOS had a large number of
bisphosphonate users in comparison to other population‐based
studies (more than 40% of women).(18) This relatively large
number of bisphosphonate users permitted an analysis of
bisphosphonates according to their class, as well as adjustment
for a large set of risk factors. The long follow‐up permitted an
investigation of the role of bone loss on mortality risk and its role
in mediating mortality reduction in individuals treated with
bisphosphonates. However, there are some limitations. Treatment
was not randomly allocated and thus part of the observed
association between treatment and survival could be related to
confounding. The treated group had significantly higher baseline
fracture risk (ie, lower BMD and weight, more prior fractures) and
had a different comorbidity profile from the nontreated group. To
counteract these selection biases, this study used propensity score
matching based on both baseline variables, which, similar to
randomization, is designed to produce groups with similar
baseline risk, while acknowledging that there still may remain
unknown confounders. The technique resulted in groups with
similar baseline characteristics, albeit few exceptions. However,
none of the imbalanced factors were associated with mortality
risk. Nevertheless, these factors may reduce the generalizability of
these findings. Lastly, mediation analysis findings need to be
interpreted through the light of its limitations. Mediation analysis
has been developed to test a causal association. However,
causality cannot be proven in an epidemiological study. In this
context, our analyses have only demonstrated that the data aligns
with the proposed causal hypothesis.
In summary, in this long‐term prospective population‐
based study, nitrogen bisphosphonate use in women was
associated with both better survival and a significant
reduction in the rate of bone loss. Bone loss was
significantly associated with increased mortality risk with
those in the highest quartile of bone loss being twice as
likely to die compared with those who did not lose bone.
Using a mediation analysis approach, approximately 39% of
the difference in mortality rates between treatment groups
was found to be related to the greater bone loss in the
nontreated versus the treated groups.
In conclusion, this study offers a plausible explanation for the
association between potent antiresorptive medication and
survival. Future mechanistic studies into osteoporosis, anti-
resorptive treatment, and survival are warranted.
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